Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 49-54

  Larochelle, Jean ^a   Alvarez, Fernando ^b   Bussières, Jean François ^b   Chevalier, Isabelle ^b   Dallaire, Louis ^b   Dubois, Josée ^b   Faucher, Frédéric ^b   Fenyves, Daphna ^c   Goodyer, Paul ^d   Grenier, André ^e   Holme, Elisabeth ^f   Laframboise, Rachel ^e   Lambert, Marie ^b   Lindstedt, Sven ^f   Maranda, Bruno ^g   Melançon, Serge ^d   Merouani, Aicha ^b   Mitchell, John ^d   Parizeault, Guy ^a   Pelletier, Luc ^h   Phan, Véronique ^b   Rinaldo, Piero ^h   Scott, C Ronald ⁱ   Scriver, Charles ^d   Mitchell, Grant A ^b   more..

^a Gouvernement du Quebec   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Clinical trials; Hepatorenal tyrosinemia; Liver; Nitisinone; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; NITISINONE;

ADOLESCENT; ARTICLE; BLOOD CELL COUNT; BLOOD GAS; CANADA; CHILD; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; HEPATORENAL SYNDROME; HEPATORENAL TYROSINEMIA; HUMAN; HYPOGLYCEMIA; INFANT; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; NEWBORN SCREENING; OUTCOME ASSESSMENT; PHOTOPHOBIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THORAX RADIOGRAPHY; THYROID FUNCTION; TREATMENT DURATION; TYROSINEMIA;

CHILD; CHILD, PRESCHOOL; CYCLOHEXANONES; ENZYME INHIBITORS; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; LIVER; LIVER TRANSPLANTATION; NEONATAL SCREENING; NITROBENZOATES; QUEBEC; TREATMENT OUTCOME; TYROSINEMIAS;

EID: 84866148040     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.05.022     Document Type: Article

References (21)

1. Mitchell G.A., Grompe M., Lambert M., Tanguay R.M. Hypertyrosinemia. The Metabolic and Molecular Bases of Inherited Disease 2001, 1777-1806. McGraw-Hill, New York. C.S. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Lindstedt S., Holme E., Lock E.A., Hjalmarson O., Strandvik B. Treatment of hereditary tyrosinaemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992, 340:813-817.
3. Grompe M., St-Louis M., Demers S.I., Al-Dhalimy M., Leclerc B., Tanguay R.M. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N. Engl. J. Med. 1994, 331:353-357.
4. Scriver C.R. Human genetics: lessons from Quebec populations. Annu. Rev. Genomics Hum. Genet. 2001, 2:69-101.
5. Laberge A.M., Michaud J., Richter A., et al. Population history and its impact on medical genetics in Quebec. Clin. Genet. 2005, 68(4):287-301.
6. Kim S.Z., Kupke K.G., Ierardi-Curto L., et al. Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I. J. Inherit. Metab. Dis. 2000, 23(8):791-804.
7. Holme E., Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-1,3- cyclohexanedione). J. Inherit. Metab. Dis. 1998, 21(5):507-517.
8. Mitchell G.A., Larochelle J., Lambert M., et al. Neurologic crises in hereditary tyrosinemia. N. Engl. J. Med. 1990, 322:432-437.
9. Lepage N., McDonald N., Dallaire L., Lambert M. Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population. Clin. Chem. 1997, 43(12):2397-2402.
10. Lock E.A., Gaskin P., Ellis M.K., et al. Tissue distribution of 2-(2-nitro-4- trifluoromethylbenzoyl)cyclohexane-1,3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol. Appl. Pharmacol. 1996, 141:439-447.
11. Dionisi-Vici C., Boglino C., Marcellini M., et al. Tyrosinemia type I with early metastatic hepatocellular carcinoma: combined treatment with NTBC, chemotherapy and surgical mass removal. J. Inherit. Metab. Dis. 1997, 20(Suppl. 1):3.
12. Holme E., Lindstedt S. Nontransplant treatment of tyrosinemia. Clin. Liver Dis. 2000, 4(4):805-814.
13. Masurel-Paulet A., Poggi-Bach J., Rolland M.O., et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J. Inherit. Metab. Dis. 2008, 31(1):81-87.
14. Rootwelt H., Hoie K., Berger R., Kvittingen E.A. Fumarylacetoacetate mutations in tyrosinaemia type I. Hum. Mutat. 1996, 7:239-243.
15. Ploos van Amstel J.K., Bergman A.J., van Beurden E.A., et al. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship. Hum. Genet. 1996, 97:51-59.
16. Watson M., Mann M., Lloyd-Puryear M., Rinaldo P., Howell R. Newborn screening: toward a uniform screening panel and system. Exec. Summ. Genet. Med. 2006, 8:1S-11S.
17. Allard P., Grenier A., Korson M.S., Zytkovicz T.H. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin. Biochem. 2004, 37(11):1010-1015.
18. Matern D., Magera M., Gunawardena N., Mitchell G., Hahn S., Rinaldo P. Succinylacetone analysis in blood spots by tandem mass spectrometry. J. Inherit. Metab. Dis. 2004, 27(Suppl. 1):15.
19. Sander J., Janzen N., Peter M., et al. Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin. Chem. 2006, 52(3):482-487.
20. Wilson C.J., Van Wyk K.G., Leonard J.V., Clayton P.T. Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia. J. Inherit. Metab. Dis. 2000, 23(7):677-683.
21. Grompe M. Liver repopulation for the treatment of metabolic diseases. J. Inherit. Metab. Dis. 2001, 24(2):231-244.